JP2020033360A5 - - Google Patents

Download PDF

Info

Publication number
JP2020033360A5
JP2020033360A5 JP2019186952A JP2019186952A JP2020033360A5 JP 2020033360 A5 JP2020033360 A5 JP 2020033360A5 JP 2019186952 A JP2019186952 A JP 2019186952A JP 2019186952 A JP2019186952 A JP 2019186952A JP 2020033360 A5 JP2020033360 A5 JP 2020033360A5
Authority
JP
Japan
Prior art keywords
deoxygalactonojirimycin
salt
gal
therapeutic agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019186952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020033360A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020033360A publication Critical patent/JP2020033360A/ja
Publication of JP2020033360A5 publication Critical patent/JP2020033360A5/ja
Priority to JP2021018456A priority Critical patent/JP2021098697A/ja
Pending legal-status Critical Current

Links

JP2019186952A 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン Pending JP2020033360A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021018456A JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US61/451,798 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US61/578,201 2011-12-20
US201261596165P 2012-02-07 2012-02-07
US61/596,165 2012-02-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017038469A Division JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021018456A Division JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン

Publications (2)

Publication Number Publication Date
JP2020033360A JP2020033360A (ja) 2020-03-05
JP2020033360A5 true JP2020033360A5 (enExample) 2020-04-23

Family

ID=46831259

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013557862A Pending JP2014528901A (ja) 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン
JP2019186952A Pending JP2020033360A (ja) 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン
JP2025179237A Pending JP2026035578A (ja) 2011-03-11 2025-10-24 ファブリー病の治療用投薬レジメン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013557862A Pending JP2014528901A (ja) 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン
JP2025179237A Pending JP2026035578A (ja) 2011-03-11 2025-10-24 ファブリー病の治療用投薬レジメン

Country Status (16)

Country Link
US (4) US20140219986A1 (enExample)
EP (2) EP2683382B1 (enExample)
JP (6) JP2014528901A (enExample)
KR (1) KR20140011367A (enExample)
CN (2) CN107088225A (enExample)
AU (6) AU2012229330B2 (enExample)
CA (1) CA2829947C (enExample)
CL (1) CL2013002601A1 (enExample)
EA (1) EA031874B1 (enExample)
ES (1) ES2807502T3 (enExample)
HK (1) HK1242998A1 (enExample)
MX (1) MX2013010446A (enExample)
SG (2) SG10201604757RA (enExample)
TW (3) TWI624259B (enExample)
WO (1) WO2012125402A2 (enExample)
ZA (1) ZA201306735B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2533050B3 (en) 2006-05-16 2015-06-24 Amicus Therapeutics, Inc. Treatment Options For Fabry Disease
SI2252313T1 (sl) 2008-02-12 2015-08-31 Amicus Therapeutics, Inc. Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
JP2017506520A (ja) * 2014-02-17 2017-03-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 微生物学的方法
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3335126B1 (en) 2015-08-11 2026-03-11 Cognoa, Inc. Apparatus to determine developmental progress with artificial intelligence and user input
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
JP7098529B2 (ja) * 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
CA3031249A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
EP3580700A4 (en) 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
EP3630114B1 (en) * 2017-05-30 2023-11-01 Amicus Therapeutics, Inc. Migalastat for treating fabry patients having renal impairment
KR102631805B1 (ko) 2017-05-30 2024-01-31 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
JP7555818B2 (ja) * 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
US20210315875A1 (en) * 2018-08-20 2021-10-14 Amicus Therapeutics, Inc. Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
BR112021018770A2 (pt) 2019-03-22 2022-02-15 Cognoa Inc Métodos e dispositivos de terapia digital personalizada
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
US20220313670A1 (en) * 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
HRP20260109T1 (hr) 2019-08-07 2026-03-13 Amicus Therapeutics, Inc. Migalastat za upotrebu u liječenju fabryjeve bolesti kod pacijenata koji imaju mutaciju u gla genu
US12564342B2 (en) 2019-09-06 2026-03-03 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat
WO2026043458A1 (en) 2024-08-23 2026-02-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising mi̇galastat
WO2026043459A2 (en) 2024-08-23 2026-02-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule formulations comprising migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
CN102586205A (zh) * 2003-01-31 2012-07-18 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
EP2533050B3 (en) * 2006-05-16 2015-06-24 Amicus Therapeutics, Inc. Treatment Options For Fabry Disease
CA2682441A1 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a

Similar Documents

Publication Publication Date Title
JP2020033360A5 (enExample)
JP2020073529A5 (enExample)
JP2015519329A5 (enExample)
ES3029536T3 (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
JP2014528901A5 (enExample)
ES2762250T3 (es) Tratamiento combinado del cáncer
ES2617628T3 (es) Régimen de dosificación para un agonista selectivo del receptor de S1P1
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2010526101A5 (enExample)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2006514092A5 (enExample)
JP2013541583A5 (enExample)
JP2018509419A5 (enExample)
JP2020536121A5 (enExample)
JP2020529440A5 (enExample)
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase
JP2020500864A5 (enExample)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2015522077A5 (enExample)
JP2020510043A5 (enExample)
JP2016505050A5 (enExample)
JP2008517991A5 (enExample)
ES2963784T3 (es) Uso de delgocitinib para el tratamiento del eccema crónico de manos
JP2013536206A5 (enExample)
JP2012502105A5 (enExample)